Eleven Biotherapeutics (EBIO) Stock Price, News & Analysis

Company Overview

Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 15.58 million shs
• Average Volume: 2.86 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

EBIO Stock Analysis - Frequently Asked Questions

How were Eleven Biotherapeutics' earnings last quarter?

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) posted its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03.

What other stocks do shareholders of Eleven Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eleven Biotherapeutics investors own include Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Immunomedics (IMMU), SELLAS Life Sciences Group (SLS), Sesen Bio (SESN), TransEnterix (TRXDW) and Dynavax Technologies (DVAX).

Company Calendar

• Last Earnings: 5/15/2018
• Today: 7/16/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:EBIO
• CIK: 1485003
• Web: www.elevenbio.com
• Phone: (617) 444-8550
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Optionable
• Beta: N/A